Home Tags Site specific conjugation

Tag: site specific conjugation

The Highs, Lows, and Resurgence of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) offer a way to deliver a cytotoxic or an immuno-stimulatory payload directly to tumors to maximize the anti-tumor efficacy of the payload with reduced systemic toxicities. The development of ADCs has occurred over several decades. ADCs have been through several highs and lows where there was substantial excitement for the promise ADCs hold only to be followed by disinterest when there were disappointing results in the clinic. This resulted in several companies abandoning their internal ADC development efforts. Twelve ADCs globally have been approved to treat hematologic or solid tumors. The renewed interest in ADCs, is due, in part, to the recent clinical success of ADCs, the development of improved ADC technologies, and the identification of new ADC targets.

AJICAP Second-generation: Realizing Versatility and Robustness through Fc-Affinity Guided Chemical Conjugation...

Over the past decade, site-specific chemical conjugation has emerged as a promising strategy to produce antibody-drug conjugates (ADCs) in the field of oncology [1]. Daiichi-Sankyo's chemical conjugation method, which uses high drug-to-antibody ratio (DAR) technology, was approved by the U.S. Food and Drug Administration as the first site-specific ADC (fam-trastuzumab-deruxtecan-nxki; Enhertu® | Daiichi Sankyo and AstraZeneca).

Advances in the Development of Dual-Drug Antibody Drug Conjugates

Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).

CStone Pharmaceuticals and LegoChem Biosciences Enter Global Licensing Agreement for...

Suzhou (China-) based CStone Pharmaceuticals and LegoChem Biosciences have signed a global licensing agreement in which CStone acquires exclusive rights for development and commercialization...

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....
Photo: Exhibition - Bird's Eye Overview. The 15th annual PEGS: The Essential Protein Engineering Summit brought more than 2,700 world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions to the Seaport World Trade Center in Boston, MA this past April 8-12, 2019, setting record-breaking attendance. Photo courtesy: CHI/PEGS

PEGS: Novel Technology to Enhance Cell Line Productivity and Expand the...

During the 16th Annual PEGS Boston Virtual Conference & Expo, which took place between August 31 – September 4, 2020, Gregory Bleck, Ph.D., Global...

BrickBio’s Novel Therapeutic Conjugation Platform Validated at Commercial Scale

Boston-based BrickBio has demonstrated its ability to insert unnatural amino acids (UAAs; called "attachment bricks"), at any site, specifically, within a protein or antibody...
Ajinomoto Bio-Pharma Services has established a high-containment bioconjugate manufacturing facility for the production and fill and finish of Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC). The facility, developed by SKAN AG, has been designed for safe handling and manipulation of very low OEL compounds (down to 1 ng/m3) while maintaining aseptic conditions and cGMP compliance. Photo courtesy: © 2020 Ajinomoto Bio-Pharma.

Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality...

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...
HPAPI Lab at Abzena. Photo Courtesy: 2019 Abzena.

Addressing the Challenges of Bioconjugate Medicines

Abstract The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the...

New ADC Payload Platform – Synaffix Launches toxSYN™

The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...

X